MCRB - Seres Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

MCRB is currently covered by 1 analysts with an average price target of $22. This is a potential upside of $20.67 (1554.14%) from yesterday's end of day stock price of $1.33.

Seres Therapeutics's activity chart (see below) currently has 68 price targets and 71 ratings on display. The stock rating distribution of MCRB is 100% BUY.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 55.6% of the time, taking 304.13 days on average.

Highest price target for MCRB is $22, Lowest price target is $22, average price target is $22.

Most recent stock forecast was given by JOHN NEWMAN from CANACCORD on 13-Mar-2026. First documented stock forecast 22-Oct-2015.

Currently out of the existing stock ratings of MCRB, 1 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 10-Aug-2020

$22

$20.6 (1471.43%)

$22

8 months 6 days ago
(13-Mar-2026)

1/5 (20%)

$13.37 (154.92%)

55

Buy Since 09-Jul-2021

$6

1 years 6 months 11 days ago
(08-May-2025)

1/5 (20%)

$-0.96 (-13.79%)

400

Sell Since 14-Mar-2025

1 years 8 months 5 days ago
(14-Mar-2025)

3/3 (100%)

$-1 (-3.85%)

119

Sell Since 24-Oct-2024

$140

2 years 26 days ago
(24-Oct-2024)

0/1 (0%)

$11.2 (8.70%)

Buy Since 03-Nov-2023

$4

2 years 5 months 12 days ago
(07-Jun-2024)

4/4 (100%)

$-16.6 (-80.58%)

680

Show more analysts

Please expand the browser size to see the chart

What is MCRB (Seres Therapeutics) average time for price targets to be met?

On average it took 304 days for the stock forecasts to be reached, with an average price target met ratio of 55.6%.

Which analyst most recently updated their price target on MCRB (Seres Therapeutics)?

John Newman

Which analyst has the most public recommendations on MCRB (Seres Therapeutics)?

John Newman works at CANACCORD and has 11 price targets and 7 ratings on MCRB

Which analyst is the currently most bullish on MCRB (Seres Therapeutics)?

Gbola Amusa with the highest potential upside of $598.6

Which analyst is the currently most reserved on MCRB (Seres Therapeutics)?

Keay Nakae with the lowest potential downside of -$1.08
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?